S1 Dataset - by Riham Saud Alhazmy (19697677)

“…</p><p>Results</p><p>The mean HbA1c level decreased from 8.61 ± 1.70 to 7.92 ± 1.60 after implementing the WhatsApp group instructions; the values showed a significant difference (t-value = 5.107 and <i>P</i>-value < 0.001). …”

Particepant recruitment flowchart. by Riham Saud Alhazmy (19697677)

“…</p><p>Results</p><p>The mean HbA1c level decreased from 8.61 ± 1.70 to 7.92 ± 1.60 after implementing the WhatsApp group instructions; the values showed a significant difference (t-value = 5.107 and <i>P</i>-value < 0.001). …”

Flow of participants through the study. by Sedighe Esmaeilzadeh (21100668)

“…Furthermore, melatonin significantly decreased sleep latency, exhibiting a large effect size, and contributed to a medium reduction in the use of sleep medications. …”

Demographic Characteristics of Participants. by Sedighe Esmaeilzadeh (21100668)

“…Furthermore, melatonin significantly decreased sleep latency, exhibiting a large effect size, and contributed to a medium reduction in the use of sleep medications. …”

CONSORT diagram. by Aina Gabarrell-Pascuet (17696594)

“…Statistically significant (<i>p</i><0.01) decreases in emotional loneliness and depressive symptoms were observed following the intervention. …”

A typical cross signalized intersection. by Bin Zhao (276445)

“…Numerical experiments using actual survey data from Kunshan City yield several noteworthy findings: (1) An optimal moderate-sized time step exists for rolling optimization to minimize either the average delay time or total costs; specifically, an excessively small time step may increase vehicle average delay time or total costs; (2) The percentage of delay reduction achieved by our method, compared to Synchro software, reaches a maximum of approximately 70% when traffic demand is moderate and the initial state is low; and (3) The percentage reduction in average delay or total costs compared to Synchro initially increases and then decreases with rising traffic intensity.…”

Survival function analysis of mortality for Viral load status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Multivariate Cox proportional hazard analysis ratio of patient factors associated with treatment outcomes in HIV care, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of treatment Interruption for Viral load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of viral suppression for BMI status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Schematic presentation of sampling of population for analysis. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of mortality and viral load suppression by demographic characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of ART treatment interruption and LTFU by clinical characteristics <i>among participants in HIV care Facilities in</i> Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of ART treatment interruption and LTFU by demographic characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of mortality and viral load suppression by clinical characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Cumulative treatment outcomes prevalence rates for patients in ART treatment from year 2020 to 2022 for study participant in Bauchi State. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis for LTFU according to Viral Load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Annual incidence rate per 100 person-years trend for ART treatment outcomes. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Western blotting identification of expression level of pyroptosis protein Gasdermin D (GSDMD) in IIL ESP-treated Caco-2 cells. by Qi Qi Lu (17721401)

Adverse event list. by Stefan Halbherr (21353882)

“…No statistically significant improvements were seen in the Montreal Cognitive Assessment (MoCA) (mean decrease −0.73; 95% CI; −2.1, 0.62; <i>p</i> = 0.255), Epworth Sleepiness Scale (mean increase 0.09; 95% CI; −2.6, 2.8; <i>p</i> > 0.999), Beck Depression Inventory (BDI) (mean decrease −1.27; 95% CI; −3.8, 1.3; <i>p</i> = 0.257), and the Starkstein Apathy Scale (mean increase 0.36; 95% CI; −1.6, 2.4; <i>p</i> = 0.822). …”